Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_provenance.
- NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_provenance.
- NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_assertion evidence source_evidence_literature NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_provenance.
- NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_assertion SIO_000772 9676019 NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_provenance.
- NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_assertion wasDerivedFrom befree-2016 NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_provenance.
- NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_assertion wasGeneratedBy ECO_0000203 NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_provenance.
- befree-2016 importedOn "2016-02-19" NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_provenance.